Cortiment® – first oral budesonide for the treatment of mild to middle active ulcerative colitis
Authors:
M. Lukáš
Authors place of work:
Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s., Praha
Published in the journal:
Gastroent Hepatol 2016; 70(1): 95-96
Category:
Drug Profile
doi:
https://doi.org/10.14735/amgh201695
Zdroje
1. Ferring Pharmaceuticals. CORTIMENT 9 mg SPC. [online]. Available from: www.medicines.org.uk/emc/medicine/30253.
2. Sandborn WJ, Travis S, Moro L et al. Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study. Gastroenterology 2012; 143(5): 1218– 1226. doi: 10.1053/ j.gastro.2012.08.003.
3. Travis SP, Danese S, Kupcinskas L et al. Once-daily budesonide MMX in active, mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut 2014; 63(3): 433– 441. doi: 10.1136/gutjnl-2012-304258.
4. Fiorino G, Fries W, De La Rue SA et al. New drug delivery systems in inflammatory bowel disease: MMX and tailored delivery to the gut. Curr Med Chem 2010; 17(17): 1851– 1857.
Štítky
Paediatric gastroenterology Gastroenterology and hepatology SurgeryČlánok vyšiel v časopise
Gastroenterology and Hepatology
2016 Číslo 1
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
- Current Insights into the Antispasmodic and Analgesic Effects of Metamizole on the Gastrointestinal Tract
- Obstacle Called Vasospasm: Which Solution Is Most Effective in Microsurgery and How to Pharmacologically Assist It?
Najčítanejšie v tomto čísle
- Cortiment® – first oral budesonide for the treatment of mild to middle active ulcerative colitis
- Faecal microbial transplantation in inflammatory bowel disease
- Long-term functional outcomes and quality of life after restorative proctocolectomy and ileal pouch-anal anastomosis
- Immunopathological complications of anti-TNF-α biological treatment